Market Overview

Meda Board Issues Statement Confirming Contact by Mylan, Rejection of Proposal

Related MYL
Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
Abbott Posts Slight Q3 Beat, Narrows Outlook
Best And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry (Investor's Business Daily)

This statement is made by the Board of Directors (the ”Board”) of Meda AB pursuant to the Securities Markets Act and/or the Financial Instruments Trading act.

The Board hereby confirms that it has been contacted by Mylan, Inc. (NYSE: MYL) regarding an indicative proposal to combine the two businesses. The Board has convened and has decided to reject the proposal. All continued discussions between Meda and Mylan have been terminated without further actions.

The Board of Directors

Posted-In: News M&A


Related Articles (MYL)

View Comments and Join the Discussion!